Article
Implant not recommended in UK, but to be launched in European market
The fluocinolone acetonide intravitreal implant (Iluvien, Alimera) has not met the UK’s cost-effectiveness thresholds for treating DME. Alimera has, however, signed an agreement with Quintiles for the implant’s European launch.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
